Session Details
[O7]Oral Presentation 7
Sat. Sep 26, 2026 4:20 PM - 5:10 PM JST
Sat. Sep 26, 2026 7:20 AM - 8:10 AM UTC
Sat. Sep 26, 2026 7:20 AM - 8:10 AM UTC
Room 4(3F Conference Room 302B)
Chair:Masanori Isogawa, Teiji Sawa
[O7-01]mRNAインフルエンザワクチンの非翻訳領域の検討
*Asumi Kanda1, Tomohiro Narahara1, Nagisa Nakata1, Ryotarou Mitsumata1 (1. Vaccine Research Sec. Life Innovation Denka Co.,Ltd.)
[O7-02]mRNA-LNP製剤における脂質組成の検討
*Nagisa Nakata1, Asumi Kanda1, Tomohiro Narahara1, Ryotarou Mitsumata1 (1. Vaccine Research Sec. Life Innovation Denka Co.,Ltd.)
[O7-03]Development of mRNA/LNP immunotherapy targeting the Pseudomonas aeruginosa type III secretion system
*Teiji Sawa1, Mao Kinoshita1, Ken Kawaguchi1, Satoshi Uchida2 (1. Kyoto Prefectural University of Medicine, 2. Science Tokyo)
[O7-04]T細胞応答増強効果と安全性向上を両立したサイトカイン併用型mRNAがんワクチンの開発
*Wakana Inoue1,2, Tatsuya Karaki2,3, Toshiro Hirai1,2,4,5, Yasuo Yoshioka1,2,3,4,5 (1. Graduate School of Pharmaceutical Sciences, The University of Osaka, 2. Research Institute for Microbial Diseases, The University of Osaka, 3. The Research Foundation for Microbial Diseases of Osaka University, 4. Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka, 5. Center for Advanced Modalities and DDS, The University of Osaka /CAMaD, Osaka Univ.)
[O7-05]EAGLアッセイを用いた細胞性免疫応答の中長期的なモニタリングはCOVID-19 mRNAワクチンがブレイクスルー感染後の症状に与える影響を明らかにする
*Taro Saito1, Arnaud Couzinet2, Toshihiro Suzuki2, Kei Miyakawa3, Tetsuya Nakatsura2 (1. Canon Medical Diagnostics Corp. R&D Div., 2. Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, 3. Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Musashimurayama)